|
SLC39A9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.14740464194097E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.10849995849094E-10 |
| Normal-vs-Stage2 |
1.087240E-01 |
| Normal-vs-Stage3 |
1.0211054224385E-11 |
| Normal-vs-Stage4 |
1.13139497770476E-11 |
| Stage1-vs-Stage2 |
4.958200E-03 |
| Stage1-vs-Stage3 |
9.274200E-02 |
| Stage1-vs-Stage4 |
7.537800E-03 |
| Stage2-vs-Stage3 |
4.804800E-04 |
| Stage2-vs-Stage4 |
7.50230000000629E-05 |
| Stage3-vs-Stage4 |
3.445400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.04201108747293E-14 |
| Normal-vs-AfricanAmerican |
1.859780E-03 |
| Normal-vs-Asian |
1.35580002780245E-09 |
| Caucasian-vs-AfricanAmerican |
1.225410E-01 |
| Caucasian-vs-Asian |
8.999800E-01 |
| AfricanAmerican-vs-Asian |
1.669610E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.29429999629861E-09 |
| Normal-vs-Female |
1.1426004586923E-10 |
| Male-vs-Female |
9.509000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63129953989483E-10 |
| Normal-vs-Age(41-60Yrs) |
3.56310003724047E-09 |
| Normal-vs-Age(61-80Yrs) |
2.72079999974473E-07 |
| Normal-vs-Age(81-100Yrs) |
1.142460E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.930000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.550800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.970800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.921600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.520000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.319400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.08739999999485E-05 |
| Classical-VS-Follicular |
1.90234999999372E-05 |
| Classical-VS-Other |
3.633600E-01 |
| Classical-VS-Normal |
1.81532566756459E-12 |
| Tall-VS-Follicular |
9.77810055147188E-11 |
| Tall-VS-Other |
2.770600E-01 |
| Tall-VS-Normal |
2.30926389122033E-14 |
| Follicular-VS-Other |
3.179400E-03 |
| Follicular-VS-Normal |
5.794200E-02 |
| Other-VS-Normal |
7.614700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.4699999999479E-06 |
| Normal-vs-N1 |
5.1281201507436E-13 |
| N0-vs-N1 |
2.29370000000007E-05 |
|
|
